Log in
Enquire now
‌

US Patent 11643446 Progranulin variants

Patent 11643446 was granted and assigned to Denali Therapeutics on May, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
Denali Therapeutics
Denali Therapeutics
0
Date Filed
March 17, 2022
0
Date of Patent
May 9, 2023
0
Patent Applicant
Denali Therapeutics
Denali Therapeutics
0
Patent Application Number
17697771
0
Patent Citations
‌
US Patent 10808036 Anti-transferrin receptor antibodies and methods of use
0
‌
US Patent 10870837 Fusion proteins comprising enzyme replacement therapy enzymes
0
‌
US Patent 11124567 Anti-TREM2 antibodies and methods of use thereof
0
Patent Citations Received
‌
US Patent 11912778 Methods of engineering transferrin receptor binding polypeptides
0
‌
US Patent 11866742 Fusion proteins comprising enzyme replacement therapy enzymes
0
Patent Inventor Names
Gunasekaran Kannan
0
Ray L. Y. Low
0
Rachel Prorok
0
Ankita Srivastava
0
Gerald Maxwell Cherf
0
Katrina W. Lexa
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11643446
0
Patent Primary Examiner
‌
Gregory S Emch
0
CPC Code
‌
C07K 2319/30
0
‌
C07K 14/475
0

Find more entities like US Patent 11643446 Progranulin variants

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us